MVZ W8 Onkologische Praxis
- Address
- Weberstrasse 8, 52064 Aachen, Germany
MVZ W8 Onkologische Praxis - Hematologic Malignancies Center
MVZ W8 Onkologische Praxis is a specialized oncology practice with expertise in hematologic malignancies, particularly focusing on lymphoma research and treatment. The center participates in advanced Phase 3 international clinical trials evaluating novel therapeutic combinations for patients with rare blood cancers.
- Mantle Cell Lymphoma treatment with targeted therapies and immunochemotherapy
- Combination regimens incorporating BTK inhibitors with standard chemoimmunotherapy
- First-line treatment protocols for previously untreated lymphoma patients
The practice demonstrates commitment to advancing treatment options for patients with Mantle Cell Lymphoma, a rare and aggressive form of non-Hodgkin lymphoma. Through participation in randomized, placebo-controlled studies, MVZ W8 contributes to evaluating innovative combinations such as acalabrutinib with bendamustine and rituximab, aiming to improve progression-free survival outcomes for patients receiving first-line therapy. This research focus positions the center at the forefront of precision medicine approaches in hematologic oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ W8 Onkologische Praxis
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial | University Of Cologne | Phase III | Not Recruiting | Jul 2016 | Dec 2024 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acalabrutinib | 1 | Unknown | 2017-07-14 | 2017-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.